On Jun. 25, 2024, Evotec announced that its Seattle-based subsidiary, Just – Evotec Biologics, was selected by the U.S. Department of Defense (DOD) to develop an accelerated monoclonal antibody (“mAb”) development and manufacturing solution for the DOD’s Manufacturing Optimization Program.

The multi-year program award, valued up to $ 39 million, will support the U.S. Government’s effort to enhance its rapid response capabilities for biologics medical countermeasures.

With the site, Just – Evotec Biologics will be able to supply small and large quantities of high quality clinical or commercial grade biologics to meet the needs of its customers and partners. Fast and efficient change-over times will provide partners with the flexibility and security to produce portfolios of biologics.